psalexa
P&S Market Research - A market research firm

Muscle Relaxant Drugs Market

Global Muscle Relaxant Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020 – Industry Insights by Facial Aesthetic Relaxant Drug (Botox, Dysport, and Others), By Skeletal Muscle Relaxant Drug (Baclofen, Methocarbamol, Carisoprodol, Metaxalone, Tizanidine, and Others), and by Neuromuscular Blocking Agent (Non-depolarizing Agents, and Depolarizing Agents)

Published: January 2016
Report Code: LS10563
Available Format:
Pages: 87

The global muscle relaxant drugs market is expected to grow with a CAGR of 5.5% during 2015 - 2020. Based on type, the global muscle relaxant drugs market was dominated by the facial aesthetic relaxant segment in 2014.

The global market of muscle relaxants is growing due to increase in geriatric population, increasing prevalence of skin diseases and harmful effects of ultra violet radiation. Old age is associated with the loss of fibrous tissue, and reduced vascular and glandular network in the layers of skin. In the elderly population, the appearance and characteristics of the skin gets altered, leading to wrinkles, appearance of frown lines, dryness, pigmentary alteration, and sagging of the skin. Muscle relaxant-based procedures help in reducing skin aging, thus giving younger look to a person by revitalizing and tightening the skin.

 

Muscle Relaxant Drugs Market

Moreover, the geriatric population is also more prone to musculoskeletal problems, compared to adults. This is due to the weakening of their muscles, which causes pains, cramps, and other muscle related problems. For the management of these aged-related musculoskeletal problems, people use prescription-based, as well as over-the-counter (OTC) drugs including muscle relaxants for their management. Thus, the growing geriatric population is fuelling the growth of the global muscle relaxants drugs market.

Moreover, the increasing usage of neuromuscular blocking agents in surgeries, and increase in disposable income are also driving the growth of the global muscle relaxant drugs market. The neuromuscular blocking agents are used in the post-operative anesthetic practices. Moreover, the administration of neuromuscular blocking agents is the initial step of the surgeries.

The usage of neuromuscular blocking agents in the operating room is quite common and holds importance in the surgeries. The neuromuscular blockers are administered to anesthetized patients for providing relaxation of skeletal muscles. Moreover, they are valuable adjuncts to general anesthetics and facilitate surgeons to perform surgeries.

The restraints associated with the growth of the global muscle relaxant drugs market include high capital expenditure, stringent regulatory requirements, and risks associated with muscle relaxants. The tradition of online shopping for the muscle relaxant drugs and increasing usage of muscle relaxant drugs in the cosmetic industry are major trends observed in the global muscle relaxant drugs market.

Geographically, North America is expected to maintain its dominance in the global market of muscle relaxants drugs during 2015-2020. This is due to due to increased awareness about various types of musculoskeletal problems and their management, aging population, and increasing number of saloon and spas in the region. In addition, the increasing R&D investments and improved healthcare infrastructure are also driving the growth of market in the region.  

The Asian market of muscle relaxant drugs is expected to witness the highest growth globally, during the forecast period. This is mainly due to aging population, increasing number of surgeries, and improving healthcare infrastructure. According to the UN publication, World Population Ageing 2013, in Asia approximately 468.5 million people belonged to the age group of 60 years and above, out of which approximately 57.5 million people were aged 80 years and above.

The key companies operating in the global muscle relaxant drugs market include F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Pfizer Inc., Galderma S.A., and Merck & Co. Inc.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 4500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 5500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 8500

Pre-Purchase Enquiry